Please use this identifier to cite or link to this item: https://doi.org/10.3390/cancers13174486
Title: Targeting cd82/kai1 for precision therapeutics in surmounting metastatic potential in breast cancer
Authors: Viera, Maximillian 
Yip, George Wai Cheong 
Shen, Han-Ming 
Baeg, Gyeong Hun 
Bay, Boon Huat 
Keywords: CD82 mimics
Epigenetic drugs
Etoposide
Metastasis suppressor
Tetraspanins
Tyrosine kinase inhibitors
Issue Date: 6-Sep-2021
Publisher: MDPI
Citation: Viera, Maximillian, Yip, George Wai Cheong, Shen, Han-Ming, Baeg, Gyeong Hun, Bay, Boon Huat (2021-09-06). Targeting cd82/kai1 for precision therapeutics in surmounting metastatic potential in breast cancer. Cancers 13 (17) : 4486. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers13174486
Rights: Attribution 4.0 International
Abstract: Metastasis is the main cause of mortality in breast cancer patients. There is an unmet need to develop therapies that can impede metastatic spread. Precision oncology has shown great promise for the treatment of cancers, as the therapeutic approach is tailored to a specific group of patients who are likely to benefit from the treatment, rather than the traditional approach of “one size fits all”. CD82, also known as KAI1, a glycoprotein belonging to the tetraspanin family and an established metastasis suppressor, could potentially be exploited to hinder metastases in breast cancer. This review explores the prospect of targeting CD82 as an innovative therapeutic approach in precision medicine for breast cancer patients, with the goal of preventing cancer progression and metastasis. Such an approach would entail the selection of a subset of breast cancer patients with low levels of CD82, and instituting an appropriate treatment scheme tailored towards restoring the levels of CD82 in this group of patients. Proposed precision treatment regimens include current modalities of treating breast cancer, in combination with either clinically approved drugs that could restore the levels of CD82, CD82 peptide mimics or non-coding RNA-based therapeutics. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Source Title: Cancers
URI: https://scholarbank.nus.edu.sg/handle/10635/233137
ISSN: 2072-6694
DOI: 10.3390/cancers13174486
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cancers13174486.pdf1.42 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons